Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Cosphiadi Irawan, Martha Iskandar, Agnes Stephanie Harahap, Cleopas Martin Rumende & Maria Francisca Ham. (2022) MUM1 Expression versus Hans Algorithm to Predict Prognosis in Indonesian Diffuse Large B-Cell Lymphoma Patients Receiving R-CHOP. Cancer Management and Research 14, pages 925-935.
Read now
Read now
Jozef Malysz, Juanita J Evans, Malcolm Acon-Laws, Michael G Bayerl & Michael H Creer. (2017) Different expression of MIB1 in primary site of non-Hodgkin lymphoma and its bone marrow deposits, a pilot study. Pathology and Laboratory Medicine International 9, pages 31-35.
Read now
Read now
Young Wha Koh, Hee Sang Hwang, Chan-Sik Park, Dok Hyun Yoon, Cheolwon Suh & Jooryung Huh. (2015) Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients. Leukemia & Lymphoma 56:9, pages 2630-2636.
Read now
Read now
Hyun Jung Lee, Dong Hoon Shin, Kyung Bin Kim, Nari Shin, Won Young Park, Jung Hee Lee, Kyung Un Choi, Jee Yeon Kim, Chang Hun Lee & Mee Young Sol. (2014) Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leukemia & Lymphoma 55:9, pages 2056-2063.
Read now
Read now
Olga Khoudoleeva, Eugeny Gretsov, Natasha Barteneva & Ivan Vorobjev. (2011) Proliferative index and expression of CD38, Zap-70, and CD25 in different lymphoid compartments of chronic lymphocytic leukemia patients. Pathology and Laboratory Medicine International 3, pages 7-16.
Read now
Read now
Chaido Sirinian, Argiris Symeonidis, Nikolaos Giannakoulas, Vassiliki Zolota & Maria Melachrinou. (2011) Overexpression of phosphorylated p27Kip1 at threonine 187 may predict outcome in aggressive B-cell lymphomas. Leukemia & Lymphoma 52:5, pages 814-822.
Read now
Read now
Articles from other publishers (23)
Shahroo Etemad-Moghadam, Ali Ghaseminejad-Bandpey, Habibollah Mahmoodzadeh & Mojgan Alaeddini. (2022) Clinicopathologic significance of DNA replication licensing factors in head and neck diffuse large B-cell lymphoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 133:4, pages 462-469.
Crossref
Crossref
Fabian Huber, Elisabeth Zwickl-Traxler, Martin Pecherstorfer & Josef Singer. (2021) Evaluation of Ki-67 as a Prognostic Marker in Diffuse Large B-Cell Lymphoma—A Single-Center Retrospective Cohort Study. Current Oncology 28:6, pages 4521-4529.
Crossref
Crossref
Atif A Hashmi, Syeda N Iftikhar, Gul Nargus, Omer Ahmed, Ishaq Azeem Asghar, Umme Aiman Shirazi, Anoshia Afzal, Muhammad Irfan & Javaria Ali. (2021) Ki67 Proliferation Index in Germinal and Non-Germinal Subtypes of Diffuse Large B-Cell Lymphoma. Cureus.
Crossref
Crossref
Feras Zaiem, Rada Jerbi, Omar Albanyan, Jordyn Puccio, Zyad Kafri, Jay Yang & Ali M Gabali. (2021) High Ki67 proliferation index but not cell-of-origin subtypes is associated with shorter overall survival in diffuse large B-cell lymphoma. Avicenna Journal of Medicine 10:04, pages 241-248.
Crossref
Crossref
Antonio Giovanni Solimando, Tiziana Annese, Roberto Tamma, Giuseppe Ingravallo, Eugenio Maiorano, Angelo Vacca, Giorgina Specchia & Domenico Ribatti. (2020) New Insights into Diffuse Large B-Cell Lymphoma Pathobiology. Cancers 12:7, pages 1869.
Crossref
Crossref
Osman Kupik, Serkan Akin, Murat Tuncel, Gülnihan Eren, Alev Türker, Ayşe Kars & Belkis Erbaş. (2020) Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lymphoma. Nuclear Medicine Communications 41:6, pages 540-549.
Crossref
Crossref
Xin-Yu Zhang, Jin-Hua Liang, Li Wang, Hua-Yuan Zhu, Wei Wu, Lei Cao, Lei Fan, Jian-Yong Li & Wei Xu. (2018) DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma. Journal of Cancer Research and Clinical Oncology 145:1, pages 117-127.
Crossref
Crossref
Dan-ming Wei, Wen-jie Chen, Rong-mei Meng, Na Zhao, Xiang-yu Zhang, Dan-yu Liao & Gang Chen. (2018) Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients. Respiratory Research 19:1.
Crossref
Crossref
Yun-Long Tang, Yan Zhou, Ling-Ling Cheng, Yong-Zhong Su & Chun-Bin Wang. (2017) BCL2/Ki-67 index predict survival in germinal center B-cell-like diffuse large B-cell lymphoma. Oncology Letters 14:3, pages 3767-3773.
Crossref
Crossref
Xin He, Zhigang Chen, Tao Fu, Xueli Jin, Teng Yu, Yun Liang, Xiaoying Zhao & Liansheng Huang. (2014) Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer 14:1.
Crossref
Crossref
Brian Thabile FlepisiPatrick BouicGerhard SissolakBernd Rosenkranz. (2014) Biomarkers of HIV-associated Cancer. Biomarkers in Cancer 6, pages BIC.S15056.
Crossref
Crossref
E Frei, C Visco, Z Y Xu-Monette, S Dirnhofer, K Dybkær, A Orazi, G Bhagat, E D Hsi, J H van Krieken, M Ponzoni, R S Go, M A Piris, M B Møller, K H Young & A Tzankov. (2013) Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. Journal of Clinical Pathology 66:11, pages 956-961.
Crossref
Crossref
Mark A. Samols, Nathan E. Smith, Jonathan M. Gerber, Milena Vuica-Ross, Christopher D. Gocke, Kathleen H. Burns, Michael J. Borowitz, Toby C. Cornish & Amy S. Duffield. (2013) Software-Automated Counting of Ki-67 Proliferation Index Correlates With Pathologic Grade and Disease Progression of Follicular Lymphomas. American Journal of Clinical Pathology 140:4, pages 579-587.
Crossref
Crossref
Judy Yan & Damu Tang. 2013. Proteins of the Nucleolus. Proteins of the Nucleolus
275
304
.
Chin-Chuan Chang, Shih-Feng Cho, Yu-Wen Chen, Hung-Pin Tu, Chia-Yang Lin & Chao-Sung Chang. (2012) SUV on Dual-Phase FDG PET/CT Correlates With the Ki-67 Proliferation Index in Patients With Newly Diagnosed Non-Hodgkin Lymphoma. Clinical Nuclear Medicine 37:8, pages e189-e195.
Crossref
Crossref
Zhi‐Ming Li, Jia‐Jia Huang, Yi Xia, Ying‐Jie Zhu, Wei Zhao, Wen‐Xiao Wei, Wen‐Qi Jiang, Tong‐Yu Lin, Hui‐Qiang Huang & Zhong‐Zhen Guan. (2012) High Ki‐67 expression in diffuse large B‐cell lymphoma patients with non‐germinal center subtype indicates limited survival benefit from R‐CHOP therapy. European Journal of Haematology 88:6, pages 510-517.
Crossref
Crossref
Francesco Gaudio, Annamaria Giordano, Tommasina Perrone, Domenico Pastore, Paola Curci, Mario Delia, Anna Napoli, Clara de’ Risi, Alessandro Spina, Rosalia Ricco, Vincenzo Liso & Giorgina Specchia. (2011) High Ki67 Index and Bulky Disease Remain Significant Adverse Prognostic Factors in Patients with Diffuse Large B Cell Lymphoma before and after the Introduction of Rituximab. Acta Haematologica 126:1, pages 44-51.
Crossref
Crossref
Devon S Chabot-Richards, David R Martin, Orrin B Myers, David R Czuchlewski & Kristin E Hunt. (2011) Quantitative image analysis in the assessment of diffuse large B-cell lymphoma. Modern Pathology 24:12, pages 1598-1605.
Crossref
Crossref
Dok Hyun Yoon, Dae Ro Choi, Heui June Ahn, Shin Kim, Dae Ho Lee, Sang‐We Kim, Bong‐Hee Park, Sun Och Yoon, Jooryung Huh, Sang‐Wook Lee & Cheolwon Suh. (2010) Ki‐67 expression as a prognostic factor in diffuse large B‐cell lymphoma patients treated with rituximab plus CHOP. European Journal of Haematology 85:2, pages 149-157.
Crossref
Crossref
Sverker Hasselblom, Ulrika Hansson, Markus Olsson, Leif Torén, Anders Bergström, Herman Nilsson-Ehle & Per-Ola Andersson. (2010) High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. British Journal of Haematology 149:4, pages 560-568.
Crossref
Crossref
E C Obermann, M Csato, S Dirnhofer & A Tzankov. (2009) BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma. Journal of Clinical Pathology 62:10, pages 903-907.
Crossref
Crossref
J. Han van Krieken. (2009) New developments in the pathology of malignant lymphoma: a review of the literature published from August to December 2008. Journal of Hematopathology 2:1, pages 50-61.
Crossref
Crossref
Vera Uzurov-Dinic, Aleksandar Savic, Tanja Lazarevic, Vesna Cemerikic-Martinovic, Danijela Agic & Stevan Popovic. (2009) Prognostic factors in patients with diffuse large B-cell lymphoma. Medicinski pregled Medical review 62:3-4, pages 171-176.
Crossref
Crossref